<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
	<Article>
		<Journal>
			<PublisherName/>
			<JournalTitle>IJOTM</JournalTitle>
			<Issn>2008-6490</Issn>
			<Volume>6</Volume>
			<Issue>2</Issue>
			<PubDate PubStatus="epublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>26</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance</ArticleTitle>
		<FirstPage>55</FirstPage>
		<LastPage>60</LastPage>
		<Language>EN</Language>
		<AuthorList>
			<Author>
				<FirstName>B</FirstName>
				<LastName>Rajeshkumar</LastName>
			</Author>
			<Author>
				<FirstName>P</FirstName>
				<LastName>Agrawal</LastName>
			</Author>
			<Author>
				<FirstName>M</FirstName>
				<LastName>Rashighi</LastName>
			</Author>
			<Author>
				<FirstName>RF</FirstName>
				<LastName>Saidi</LastName>
				<Affiliation>Division of Organ Transplantation, Department of Surgery, Alpert Medical School of Brown University, Providence, RI, USA. reza_saidi@brown.edu</Affiliation>
			</Author>
		</AuthorList>
		<History>
			<PubDate PubStatus="received">
				<Year>2015</Year>
				<Month>03</Month>
				<Day>26</Day>
			</PubDate>
		</History>
		<Abstract>Background: Organ transplantation currently requires long-term immunosuppression. This is associated with multiple complications including infection, malignancy and other toxicities. Immunologic tolerance is considered the optimal solution to these limitations.Objective: To develop a simple and non-toxic regimen to induce mixed chimerism and tolerance using mesenchymal stem cell (MSC) in a murine model.Methods: Wild type C57BL6 (H2Dk) and Bal/C (H2Dd) mice were used as donors and recipients, respectively. We studied to achieve tolerance to skin grafts (SG) through mixed chimerism (MC) by simultaneous skin graft and non-myeloablative donor bone marrow transplantation (DBMT) +/&amp;ndash; MSC. All recipients received rapamycin and CTLA-4 Ig without radiation.Results: DBMT+MSC combined with co-stimulation blockage and rapamycin led to stable mixed chimerism, expansion of Tregs population and donor-specific skin graft tolerance. The flow cytometry analysis revealed that recipient mice developed 15%&amp;ndash;85% chimerism. The skin allografts survived for a long time. Elimination of MSC failed to induce mixed chimerism and tolerance.Conclusion: Our results demonstrate that donor-specific immune tolerance can be effectively induced by non-myeloablative DBMT-MSC combination without any additional cytoreductive treatment. This approach provides a promising and non-toxic allograft tolerance strategy.</Abstract>
	</Article>
</ArticleSet>
